Berkshire Bank Reduces Position in Pfizer Inc. $PFE

Berkshire Bank decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.8% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 16,966 shares of the biopharmaceutical company’s stock after selling 1,239 shares during the quarter. Berkshire Bank’s holdings in Pfizer were worth $411,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Gould Capital LLC grew its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the first quarter valued at $27,000. North Capital Inc. purchased a new stake in shares of Pfizer in the first quarter valued at $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the first quarter valued at $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer in the fourth quarter valued at $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.4%

NYSE:PFE opened at $23.88 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The business’s 50-day simple moving average is $24.73 and its 200 day simple moving average is $24.25. The stock has a market cap of $135.77 billion, a price-to-earnings ratio of 12.70, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 earnings per share. The company’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. Pfizer’s payout ratio is 91.49%.

Analysts Set New Price Targets

PFE has been the subject of a number of recent analyst reports. Jefferies Financial Group lifted their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Berenberg Bank lowered their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.